LY-23 is an orally active alpha-glucosidase inhibitor (Ki = 0.05 µM), with IC50 values of 0.18 µM, 0.14 µM and 0.51 µM against maltase, sucrase and isomaltase, respectively. LY-23 reduces the level of postprandial blood glucose elevation. LY-23 is applicable to research related to postprandial hyperglycemia[1].
Molekulargewicht:
505.84
Formel:
C19H27Cl3O7S
Target-Kategorie:
Glycosidase
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
